Preclinical data have shown that incorporation of costimulatory molecules into CARs helps CAR-T cells to reverse the immunosuppressive tumor microenvironment, for example, CD28 co-stimulation overcomes TGF-β-mediated repression of proliferation and enhances T-cell resistance to Treg cells 31, 32, 65. Here, CD28 is linked to neoplasm.